Rebecca Marsh

Primary Immune Deficiency Treatment Consortium (PIDTC): A Resource to Drive Scientific and Clinical Advances Related to the Treatment of Inborn Errors of Immunity

National Institute of Allergy and Infectious Diseases · R24

PI · $5.3M · University of California, San Francisco

Precision Alemtuzumab Therapy in Allogeneic HCT

National Institute of Child Health and Human Development · R01

Contact PI · $298K · Cincinnati Childrens Hosp Med Ctr

Investigations into XIAP-Deficient X-Linked Lymphoproliferative Disease

National Institute of Allergy and Infectious Diseases · R03

Contact PI · $150K · Cincinnati Childrens Hosp Med Ctr

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Principal investigator · Recruiting · Phase 1

Children's Hospital Medical Center, Cincinnati

Precision Dosing of Alemtuzumab

Principal investigator · Completed

Children's Hospital Medical Center, Cincinnati

CD34+ Stem Cell Infusion to Augment Graft Function

Principal investigator · Terminated · Phase 2

Children's Hospital Medical Center, Cincinnati